Kitov Pharma announces results of pre-clinical study of NT-219
Kitov Pharmaceuticals Holdings announced results of a pre-clinical study demonstrating that NT-219, the lead drug candidate of its subsidiary TyrNovo, in combination with Keytruda, converted non-responding tumors to responders and blocked tumor progression in an immune-oncology preclinical model. The study, conducted in collaboration with researchers at Bar Ilan University and Rabin Medical Center, assessed NT-219's ability to overcome cancer drug resistance in a patient-derived xenograft model of immune-deficient mice, in which a tumor originated from an esophagus cancer biopsy was implanted. The mice were supplemented with immune cells from the same patient. While no response was observed with Keytruda alone or with NT-219 alone, and the tumors aggressively progressed, mice treated concomitantly with a combination of Keytruda and NT-219 demonstrated complete blockage of tumor progression.